Skip to main content

Advertisement

SpringerLink
Log in

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review

  • Parkinson's Disease and Allied Conditions - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

A literature review was conducted to assess risk of cardiac valve regurgitation (CVR) associated with use of ergot-derived and non-ergot dopamine agonists (DAs) in patients with Parkinson’s disease (PD). Inclusion criteria: case-control/observational studies of >10 patients with PD treated with DAs, including a control group and assessment of incidence/risk of CVR. Of the 166 publications identified, 14 met all inclusion criteria and included 1,750 patients. In 11 of the studies, a significant increase in CVR frequency of any severity (at the aortic, mitral or tricuspid valve) in the ergot group vs. the non-ergot or control group was described. No study reported increased risk of CVR for non-ergot DAs, compared with controls. In the studies identified in the literature, the use of ergot-derived DAs (pergolide and cabergoline) in patients with PD was associated with increased risk of CVR. Increased risk of CVR was not associated with the use of non-ergot DAs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad, JP, Bertoni et al (1997) Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 49:393–399

  • Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829

    Article  PubMed  CAS  Google Scholar 

  • Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR (1974) Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 88:640–655

    Article  PubMed  CAS  Google Scholar 

  • Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63:301–304

    PubMed  CAS  Google Scholar 

  • Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by l-dopa. J Neural Transm 109:489–502

    Article  PubMed  CAS  Google Scholar 

  • Calomne V, Dupuis MJ, Muller T, Kempinere F (2004) Reversible cardiac valve abnormalities with pergolide treatment. Rev Neurol (Paris) 160:81–82

    CAS  Google Scholar 

  • Clarke CE, Guttman M (2002) Dopamine agonist monotherapy in Parkinson’s disease. Lancet 360:1767–1769

    Article  PubMed  CAS  Google Scholar 

  • Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581–588

    Article  PubMed  CAS  Google Scholar 

  • Corvol J-C, Anzouan-Kacou J-B, Fauveau E, Bonnet A-M, Lebrun-Vignes B, Girault C et al (2007) Heart valve regurgitation, pergolide use, and Parkinson disease. Arch Neurol 64:1721–1726

    Article  PubMed  Google Scholar 

  • Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374–379

    PubMed  CAS  Google Scholar 

  • Davey Smith G, Egger M (1998) Meta-analysis. Unresolved issues and future developments. BMJ 316:221–225

    PubMed  CAS  Google Scholar 

  • Dewey RBII, Reimold SC, O’Suilleabhain PE (2007) Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 64:377–380

    Article  PubMed  Google Scholar 

  • Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P et al (2005) Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline. J Neural Transm 112:661–668

    Article  PubMed  CAS  Google Scholar 

  • Egger M, Smith GD (1998) Bias in location and selection of studies. BMJ 316:61–66

    PubMed  CAS  Google Scholar 

  • Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration’s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730–731

    Article  PubMed  Google Scholar 

  • Grosset K, Needleman F, Macphee G, Grosset D (2004) Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov Disord 19:1370–1374

    Article  PubMed  Google Scholar 

  • Hendrikx M, Van Dorpe J, Flameng W, Daenen W (1996) Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 5:235–237

    PubMed  CAS  Google Scholar 

  • Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053

    Article  PubMed  Google Scholar 

  • Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S et al (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656–662

    Article  PubMed  Google Scholar 

  • Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T (2000) Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 101:2071–2077

    PubMed  CAS  Google Scholar 

  • Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH et al (2007) Valvular heart disease in Parkinson’s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234–238

    Article  PubMed  Google Scholar 

  • Kenangil G, Ozekmekci S, Koldas L, Sahin T, Erginoz E (2007) Assessment of valvulopathy in Parkinson’s disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg 109:350–353

    Article  PubMed  Google Scholar 

  • Kim JY, Chung EJ, Park SW, Lee WY (2006) Valvular heart disease in Parkinson’s disease treated with ergot derivative dopamine agonists. Mov Disord 21:1261–1264

    Article  PubMed  Google Scholar 

  • Lieberman A, Ranhosky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162–168

    Article  PubMed  CAS  Google Scholar 

  • Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S et al (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology 51:1057–1062

    PubMed  CAS  Google Scholar 

  • Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1:345–349

    Article  PubMed  CAS  Google Scholar 

  • Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791–804

    Article  PubMed  CAS  Google Scholar 

  • Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58:11–17

    Article  PubMed  CAS  Google Scholar 

  • Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H et al (2003) Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov Disord 18:1149–1156

    Article  PubMed  Google Scholar 

  • Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303:815–822

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40:340–345

    Article  PubMed  CAS  Google Scholar 

  • Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G et al (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39:11–19

    Article  PubMed  CAS  Google Scholar 

  • Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H et al (2006) Practice parameter: treatment of Parkinson’s disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:983–995

    Article  PubMed  CAS  Google Scholar 

  • Peralta C, Wolf E, Alber H, Seppi K, Muller S, Bosch S et al (2006) Valvular heart disease in Parkinson’s disease vs. controls: an echocardiographic study. Mov Disord 21:1109–1113

    Article  PubMed  Google Scholar 

  • Pinero A, Marcos-Alberca P, Fortes J (2005) Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353:1976–1977

    Article  PubMed  CAS  Google Scholar 

  • Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280–1286

    Article  PubMed  Google Scholar 

  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484–1491

    Article  PubMed  CAS  Google Scholar 

  • Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ (1992) Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 117:50–52

    PubMed  CAS  Google Scholar 

  • Ruzicka E, Linkova H, Penicka M, Ulmanova O, Novakova L, Roth J (2007) Low incidence of restrictive valvulopathy in patients with Parkinson’s disease on moderate dose of pergolide. J Neurol 254:1575–1578

    Article  PubMed  Google Scholar 

  • Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38

    Article  PubMed  CAS  Google Scholar 

  • Schwarz J (2003) Rationale for dopamine agonist use as monotherapy in Parkinson’s disease. Curr Opin Neurol 16(Suppl 1):S27–S33

    Article  PubMed  CAS  Google Scholar 

  • Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334–336

    Article  PubMed  Google Scholar 

  • Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB (1999) Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 100:2161–2167

    PubMed  CAS  Google Scholar 

  • Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83:897–902

    Article  PubMed  CAS  Google Scholar 

  • Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012

    Article  PubMed  CAS  Google Scholar 

  • Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D (2003) Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology 61:859–861

    PubMed  Google Scholar 

  • Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M et al (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183

    Article  PubMed  CAS  Google Scholar 

  • Waller EA, Kaplan J, Heckman MG (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016–1020

    Article  PubMed  CAS  Google Scholar 

  • Wilke A, Hesse H, Hufnagel G, Maisch B (1997) Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 18:701

    PubMed  CAS  Google Scholar 

  • Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67:1225–1229

    Article  PubMed  CAS  Google Scholar 

  • Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N et al (2008) The frequency of cardiac valvular regurgitation in Parkinson’s disease. Mov Disord 23:935–941

    Article  PubMed  Google Scholar 

  • Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46

    Article  PubMed  CAS  Google Scholar 

  • Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA et al (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777–802

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This review was supported by GlaxoSmithKline Research and Development. The authors take full responsibility for the content of the paper, but thank Sarah Brown for assistance with preparing the initial draft of the manuscript and collating author comments.

Author information

Authors and Affiliations

  1. The Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, Liverpool, L9 7LJ, UK

    Malcolm Steiger

  2. Department of Neurology, German Diagnostic Clinic, Aukammallee 33, 65191, Wiesbaden, Germany

    W. Jost

  3. Department of Neurology, Hospital Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain

    F. Grandas

  4. Academic Hospital, Laarbeeklaan 101, 1090, Brussels, Belgium

    G. Van Camp

Authors
  1. Malcolm Steiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Jost
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Grandas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Van Camp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malcolm Steiger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steiger, M., Jost, W., Grandas, F. et al. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review. J Neural Transm 116, 179–191 (2009). https://doi.org/10.1007/s00702-008-0179-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-008-0179-4

Keywords

Search

Navigation